Activator Protein 2α Inhibits Tumorigenicity and Represses Vascular Endothelial Growth Factor Transcription in Prostate Cancer Cells

Cancer Research

Volumn 64, Issue 2, 2004, Pages 631-638

  Ruiz, Maribelis ^a   Pettaway, Curtis ^a   Song, Renduo ^a   Stoeltzing, Oliver ^a   Ellis, Lee ^a   Bar Eli, Menashe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; GENE PRODUCT; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2ALPHA; TRANSCRIPTION FACTOR SP3; UNCLASSIFIED DRUG; VASCULOTROPIN; DNA BINDING PROTEIN; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE IDENTIFICATION; HUMAN; HUMAN CELL; MALE; MAMMAL CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; ANIMAL; CHROMATIN; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR CLONING; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROMOTER REGION; PROSTATE TUMOR; VASCULAR ENDOTHELIUM; VASCULARIZATION; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CHROMATIN; CLONING, MOLECULAR; DNA-BINDING PROTEINS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION FACTORS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1642515774     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2751     Document Type: Article

References (37)

1. American Cancer Society Cancer Facts and Figures. Atlanta: American Cancer Society, 2002.
2. Ruiz, M., Troncoso, P., Bruns, C., and Bar-Eli, M. Activator protein 2á transcription factor expression is associated with luminal differentiation and is lost in prostate cancer. Clin. Cancer Res., 7: 4086-4095, 2001.
3. Jean, D., Gershenwald, J. E., Huang, S., Luca, M., Hudson, M. J., Tainsky, M. A., and Bar-Eli, M. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J. Biol. Chem., 273: 16501-16508, 1998.
4. Huang, S., Jean, D., Luca, M., Tainsky, M. A., and Bar-Eli, M. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenecity and metastasis. EMBO J., 17: 4358-4369, 1998.
5. Karjalainen, J. M., Kellokoski, J. K., Eskelinen, M. J., Alhava, E. M., and Kosma, V. M. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J. Clin. Oncol., 16: 3584-3591, 1998.
6. Ropponen, K. M., Kellokoski, J. K., Lipponen, P. K., Pietilainen, T., Eskelinen, M. J., Alhava, E. M., and Kosma, V. M. p21/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis. Br. J. Cancer, 81: 133-140, 1999.
7. Turner, B. C., Zhang, J., Gumbs, A. A., Maher, M. G., Kaplan, L., Carter, D., Glazer, P. M., Hurst, H. C., Haffty, B. G., and Williams, T. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signaling pathways. Cancer Res., 58: 5466-5472, 1998.
8. Gee, J. M., Robertson, J. F., Ellis, I. O., Nicholson, R. I., and Hurst, H. C. Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J. Pathol., 189: 514-520, 1999.
9. Gershenwald, J. E., Sumner, W., Calderone, T., Wang, Z., Huang, S., and Bar-Eli, M. Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene, 20: 3363-3375, 2001.
10. Tellez, C., and Bar-Eli, M. Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene, 22: 3130-3137, 2003.
11. Brawer, M. K., Deering, R. E., Brown, M., Preston, S. D., and Bigler, S. A. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer (Phila.), 73: 678-687, 1994.
12. Mazzucchelli, R., Montironi, R., Santinelli, A., Lucarini, G., Pugnaloni, A., and Biagini, G. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate, 45: 72-79, 2000.
13. Matsumoto, T. and Claesson-Welsh, L. VEGF receptor signal transduction. Sci. STKE, 2001: RE21, 2001.
14. Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J., and Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem., 267: 26031-26037, 1992.
15. Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B., and Leung, D. W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol., 5: 1806-1814, 1991.
16. Poltorak, Z., Cohen, T., Sivan, R., Kandelis, Y., Spira, G., Vlodavsky, I., Keshet, E., and Neufeld, G. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem., 272: 7151-7158, 1997.
17. Lei, J., Jiang, A., and Pei, D. Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim. Biophys. Acta, 1443: 400-406, 1998.
18. Jackson, M. W., Bentel, J. M., and Tilley, W. D. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J. Urol., 157: 2323-2328, 1997.
19. Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C., and Abraham, J. A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem., 266: 11947-11954, 1991.
20. Funamoto, M., Fujio, Y., Kunisada, K., Negoro, S., Tone, E., Osugi, T., Hirota, H., Izumi, M., Yoshizaki, K., Walsh, K., Kishimoto, T., and Yamauchi-Takihara, K. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J. Biol. Chem., 275: 10561-10566, 2000.
21. Pettaway, C. A., Pathak, S., Greene, G., Ramirez, E., Wilson, M. R., Killion, J. J., and Fidler, I. J. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin. Cancer Res., 2: 1627-1636, 1996.
22. Koura, A. N., Liu, W., Kitadai, Y., Singh, R. K., Radinsky, R., and Ellis, L. M. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density. Cancer Res., 56: 3891-3894, 1996.
23. Ellis, L. M., Staley, C. A., Liu, W., Fleming, R. Y., Parikh, N. U., Bucana, C. D., and Gallick, G. E. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J. Biol. Chem., 273: 1052-1057, 1998.
24. Nyormoi, O., Wang, Z., Doan, D., Ruiz, M., McConkey, D., and Bar-Eli, M. Transcription factor AP-2α is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor á-induced apoptosis in breast cancer cells. Mol. Cell. Biol., 21: 4856-4867, 2001.
25. Zhang, L., Yu, D., Hu, M., Xiong, S., Lang, A., Ellis, L. M., and Pollock, R. E. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res., 60: 3655-3661, 2000.
26. Milanini, J., Vinals, F., Pouyssegur, J., and Pages, G. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J. Biol. Chem., 273: 18165-18172, 1998.
27. Gille, J., Swerlick, R. A., and Caughman, S. W. Transforming growth factor-á-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J., 16: 750-759, 1997.
28. Sweeney, P., Karashima, T., Kim, S. J., Kedar, D., Mian, B., Huang, S., Baker, C., Fan, Z., Hicklin, D. J., Pettaway, C. A., and Dinney, C. P. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin. Cancer Res., 8: 2714-2724, 2002.
29. Jackson, M. W., Roberts, J. S., Heckford, S. E., Ricciardelli, C., Stahl, J., Choong, C., Horsfall, D. J., and Tilley, W. D. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res., 62: 854-859, 2002.
30. Williams, T., and Tjian, R. Analysis of the DNA-binding and activation properties of the human transcription factor AP-2. Genes Dev., 5: 670-682, 1991.
31. Gille, J., Reisinger, K., Asbe-Vollkopf, A., Hardt-Weinelt, K., and Kaufmann, R. Ultraviolet-A-induced transactivation of the vascular endothelial growth factor gene in HaCaT keratinocytes is conveyed by activator protein-2 transcription factor. J. Investig. Dermatol., 115: 30-36, 2000.
32. Gille, J., Khalik, M., Konig, V., and Kaufmann, R. Hepatocyte growth factor/scatter factor (HGF/SF) induces vascular permeability factor (VPF/VEGF) expression by cultured keratinocytes. J. Investig. Dermatol., 111: 1160-1165, 1998.
33. Toyoda, M., Takayama, H., Horiguchi, N., Otsuka, T., Fukusato, T., Merlino, G., Takagi, H., and Mori, M. Overexpression of hepatocyte growth factor/scatter factor promotes vascularization and granulation tissue formation in vivo. FEBS Lett., 509: 95-100, 2001.
34. Tsai, J. C., Goldman, C. K., and Gillespie, G. Y. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J. Neurosurg., 82: 864-873, 1995.
35. Akagi, Y., Liu, W., Zebrowski, B., Xie, K., and Ellis, L. M. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-1. Cancer Res., 58: 4008-4014, 1998.
36. Majello, B., De Luca, P., and Lania, L. Sp3 is a bifunctional transcription regulator with modular independent activation and repression domains. J. Biol. Chem., 272: 4021-4026, 1997.
37. Hagen, G., Muller, S., Beato, M., and Suske, G. Sp1-mediated transcriptional activation is repressed by Sp3. EMBO J., 13: 3843-3851, 1994.